HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
bis(di-isobutyloctadecylsiloxy)silicon 2,3-naphthalocyanine
used for tumor therapy; structure given in second source
Also Known As:
bis(di-isobutyloctadecylsiloxy)-2,3-naphthalocyanato silicon; iso-BOSiNc; isoBOSINC
Networked:
4
relevant articles (
0
outcomes,
2
trials/studies)
Bio-Agent Context: Research Results
Organic Chemicals: 133
Coordination Complexes: 576
Metalloporphyrins: 178
bis(di-isobutyloctadecylsiloxy)silicon 2,3-naphthalocyanine: 4
Organosilicon Compounds: 15
bis(di-isobutyloctadecylsiloxy)silicon 2,3-naphthalocyanine: 4
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Azoles: 2138
Pyrroles: 369
Tetrapyrroles: 70
Porphyrins: 3316
Metalloporphyrins: 178
bis(di-isobutyloctadecylsiloxy)silicon 2,3-naphthalocyanine: 4
Fused-Ring Heterocyclic Compounds
4 or More Rings Heterocyclic Compounds
Tetrapyrroles: 70
Porphyrins: 3316
Metalloporphyrins: 178
bis(di-isobutyloctadecylsiloxy)silicon 2,3-naphthalocyanine: 4
Polycyclic Compounds: 6
Macrocyclic Compounds: 15
Tetrapyrroles: 70
Porphyrins: 3316
Metalloporphyrins: 178
bis(di-isobutyloctadecylsiloxy)silicon 2,3-naphthalocyanine: 4
Biological Factors: 2472
Biological Pigments: 1
Porphyrins: 3316
Metalloporphyrins: 178
bis(di-isobutyloctadecylsiloxy)silicon 2,3-naphthalocyanine: 4
Related Diseases
1.
Neoplasms (Cancer)
08/23/1991 - "
Due to its low detection limit and selectivity, the method is appropriate for pharmacokinetic as well as tumor uptake studies following in vivo exposure to isoBOSINC.
"
01/01/1996 - "
The isoBOSINC retention in tumors was high and was vehicle dependent.
"
01/01/1996 - "
The isoBOSINC was isolated from several tissues and organs, as well as tumors and peritumoral muscles and skin.
"
01/01/1994 - "
The compound isoBOSINC was isolated from several tissues and organs, as well as tumors and peritumoral muscles and skin, and quantitated by a high-performance liquid chromatographic technique.
"
01/01/1994 - "
Tissue distributions were studied in normal and in tumor-bearing rats as a function of time following intravenous injection of isoBOSINC as a suspension in 10% Tween 80 in saline.
"
2.
Fibrosarcoma
12/01/1990 - "
The pharmacokinetic behaviour and phototherapeutic effectiveness of bis(di-isobutyloctadecylsil-oxy)-2,3-naphthalocyanatosilicon (iso-BOSiNc) incorporated into dipalmitoyl-phosphatidylcholine (DPPC) liposomes have been studied in Balb/c mice bearing an MS-2 fibrosarcoma.
"
3.
Carcinoma (Carcinomatosis)
01/01/1996 - "
The tumor model was an N-(4-[5-nitro-2-furyl]-2-thiazolyl) formamide (FANFT)-induced urothelial cell carcinoma transplanted into one hind leg of male Fischer 344 rats; isoBOSINC was delivered to the rats by intravenous injection of 0.50 mg/kg of body weight as a suspension either in 10% Tween 80 in saline (Tween) or 10% (Cremophor EL + propylene glycol) in saline (Cremophor).
"
4.
Body Weight (Weight, Body)
01/01/1996 - "
The tumor model was an N-(4-[5-nitro-2-furyl]-2-thiazolyl) formamide (FANFT)-induced urothelial cell carcinoma transplanted into one hind leg of male Fischer 344 rats; isoBOSINC was delivered to the rats by intravenous injection of 0.50 mg/kg of body weight as a suspension either in 10% Tween 80 in saline (Tween) or 10% (Cremophor EL + propylene glycol) in saline (Cremophor).
"
Related Drugs and Biologics
1.
Photosensitizing Agents (Photosensitizers)
2.
Silicon
3.
2,3-naphthalocyanine
4.
Suspensions
5.
Polysorbates (PSML)
6.
Propylene Glycol (1,2 Propanediol)
7.
1,2-Dipalmitoylphosphatidylcholine (Dipalmitoylphosphatidylcholine)
8.
Liposomes (Liposome)
9.
FANFT
10.
formamide
Related Therapies and Procedures
1.
Therapeutics
2.
Intravenous Injections